Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26472
Title: | Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial | Authors: | Puccio, Giuseppe ALLIET, Philippe Cajozzo, Cinzia JANSSENS, Elke Corsello, Giovanni Sprenger, Norbert Wernimont, Susan Egli, Delphine Gosoniu, Laura Steenhout, Philippe |
Issue Date: | 2017 | Source: | JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 64(4), p. 624-631 | Abstract: | Objectives:The aim of the study was to evaluate the effects of infant formula supplemented with 2 human milk oligosaccharides (HMOs) on infant growth, tolerance, and morbidity. Methods:Healthy infants, 0 to 14 days old, were randomized to an intact-protein, cow's milk-based infant formula (control, n=87) or the same formula with 1.0g/L 2fucosyllactose (2FL) and 0.5g/L lacto-N-neotetraose (LNnT) (test, n=88) from enrollment to 6 months; all infants received standard follow-up formula without HMOs from 6 to 12 months. Primary endpoint was weight gain through 4 months. Secondary endpoints included additional anthropometric measures, gastrointestinal tolerance, behavioral patterns, and morbidity through age 12 months. Results:Weight gain was similar in both groups (mean difference [95% confidence interval] test vs control: -0.30 [-1.94, 1.34] g/day; lower bound of 95% confidence interval was above noninferiority margin [-3g/day]). Digestive symptoms and behavioral patterns were similar between groups; exceptions included softer stool (P=0.021) and fewer nighttime wake-ups (P=0.036) in the test group at 2 months. Infants receiving test (vs control) had significantly fewer parental reports (P=0.004-0.047) of bronchitis through 4 (2.3% vs 12.6%), 6 (6.8% vs 21.8%), and 12 months (10.2% vs 27.6%); lower respiratory tract infection (adverse event cluster) through 12 months (19.3% vs 34.5%); antipyretics use through 4 months (15.9% vs 29.9%); and antibiotics use through 6 (34.1% vs 49.4%) and 12 months (42.0% vs 60.9%). Conclusions:Infant formula with 2FL and LNnT is safe, well-tolerated, and supports age-appropriate growth. Secondary outcome findings showing associations between consuming HMO-supplemented formula and lower parent-reported morbidity (particularly bronchitis) and medication use (antipyretics and antibiotics) warrant confirmation in future studies. | Keywords: | 2fucosyllactose; bronchitis; lacto-N-neotetraose; safety; tolerance | Document URI: | http://hdl.handle.net/1942/26472 | ISSN: | 0277-2116 | e-ISSN: | 1536-4801 | DOI: | 10.1097/MPG.0000000000001520 | ISI #: | 000398215300035 | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jpga-64-624.pdf | Published version | 507.18 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
80
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
212
checked on Apr 30, 2024
Page view(s)
30
checked on Sep 5, 2022
Download(s)
56
checked on Sep 5, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.